Molecular biological correlation of fluorine-18 fluorodeoxyglucose uptake in esophageal squamous cell carcinoma

被引:2
作者
Hirose, Yasumitsu [1 ,2 ]
Kaida, Hayato [7 ]
Kawahara, Akihiko [4 ]
Matono, Satoru [3 ]
Tanaka, Toshiaki [3 ]
Kurata, Seiji [1 ,2 ]
Kage, Masayoshi [4 ]
Ishibashi, Masatoshi [5 ,6 ]
Abe, Toshi [1 ,2 ]
机构
[1] Kurume Univ, Sch Med, Dept Radiol, Div Nucl Med, Kurume, Fukuoka, Japan
[2] Kurume Univ, Sch Med, PET Ctr, Kurume, Fukuoka, Japan
[3] Kurume Univ, Sch Med, Dept Surg, Kurume, Fukuoka, Japan
[4] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka, Japan
[5] Fukuoka Tokushukai Hosp, Div Nucl Med, Kasuga, Fukuoka, Japan
[6] Fukuoka Tokushukai Hosp, PET Ctr, Kasuga, Fukuoka, Japan
[7] Kinki Univ, Fac Med, Dept Radiol, Ohnohigashi 377-2, Osakasayama City, Osaka 5898511, Japan
关键词
F-18-FDG PET; CT; esophageal squamous cell carcinoma; GLUT-1; GLUT-3; tumor-associated macrophages; POSITRON-EMISSION-TOMOGRAPHY; TUMOR-ASSOCIATED MACROPHAGES; ENDOTHELIAL GROWTH-FACTOR; GLUT-1; EXPRESSION; FDG-PET; SURVIVAL; ANGIOGENESIS; IMPACT; VOLUME;
D O I
10.1097/MNM.0000000000000550
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
ObjectiveThe aim of this study was to assess the relationship between fluorine-18 fluorodeoxyglucose (F-18-FDG) uptake and molecular biological markers in esophageal squamous cell carcinoma (ESCC) patients.MethodsOur patient population included 51 patients who underwent F-18-FDG PET/computed tomography before surgery. Excised tumor tissue was analyzed immunohistochemically using monoclonal antibodies for glucose transporter-1 (GLUT-1), GLUT-3, CD34 [microvessel density (MVD) marker], CD68 (macrophage marker), and CD163 (tumor-associated macrophage marker). The relationships among pathological factors [pathological T stage (p-T stage), pathological lymph node status (p-N status), pathological stage (p-stage), and pathological tumor length], the maximum standardized uptake value (SUVmax), and these molecular biological markers were evaluated using Spearman's rank test and the Kruskal-Wallis test.ResultsGLUT-1, GLUT-3, CD34, and CD163 significantly correlated with SUVmax (r=0.547, P<0.001 for GLUT-1; r=0.569, P<0.001 for GLUT-3; r=0.463, P=0.001 for CD34, r=0.455, P=0.001 for CD163), whereas SUVmax, GLUT-1, GLUT-3, CD34, and CD163 significantly correlated with p-T stage (r=0.552, P<0.001 for SUVmax, r=0.307, P=0.03 for GLUT-1, r=0.349, P=0.013 for GLUT-3, r=0.313, P=0.027 for CD34, r=0.526 for CD163, P<0.001), but not with p-N status. CD68 levels showed no significant correlation with SUVmax, p-T stage, p-stage, or p-N status.ConclusionSUV(max), GLUT-1 expression, GLUT-3 expression, MVD, and TAMs show a relationship with the tumor stage and extent of ESCC. GLUT-1, GLUT-3, MVD, and TAMs are associated with the mechanism of F-18-FDG uptake in ESCC.Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:1053 / 1061
页数:9
相关论文
共 50 条
  • [21] Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis
    Treglia, Giorgio
    Villani, Maria Felicia
    Giordano, Alessandro
    Rufini, Vittoria
    ENDOCRINE, 2012, 42 (03) : 535 - 545
  • [22] Clinical value of fluorine-18a-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET
    Horiguchi, Keishi
    Tosaka, Masahiko
    Higuchi, Tetsuya
    Arisaka, Yukiko
    Sugawara, Kenichi
    Hirato, Junko
    Yokoo, Hideaki
    Tsushima, Yoshito
    Yoshimoto, Yuhei
    EJNMMI RESEARCH, 2017, 7
  • [23] Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell Carcinoma
    Giannatempo, Patrizia
    Alessi, Alessandra
    Miceli, Rosalba
    Raggi, Daniele
    Fare, Elena
    Nicolai, Nicola
    Serafini, Gianluca
    Padovano, Barbara
    Piva, Luigi
    Biasoni, Davide
    Torelli, Tullio
    Catanzaro, Mario
    Stagni, Silvia
    Maffezzini, Massimo
    Mariani, Luigi
    Gianni, Alessandro M.
    Sonpavde, Guru
    Salvioni, Roberto
    Necchi, Andrea
    Crippa, Flavio
    CLINICAL GENITOURINARY CANCER, 2014, 12 (06) : 433 - 439
  • [24] Exploring the 18F-Fluorodeoxyglucose PET Characteristics in Staging of Esophageal Squamous Cell Carcinoma
    Ma, C.
    Yin, Y.
    MEDICAL PHYSICS, 2014, 41 (06) : 150 - +
  • [25] USING 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY TO ESTIMATE THE LENGTH OF GROSS TUMOR IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS
    Zhong, Xiaojun
    Yu, Jinming
    Zhang, Baijiang
    Mu, Dianbin
    Zhang, Weidi
    Li, Daotang
    Han, Anqin
    Song, Pingping
    Yang, Guoren
    Kong, Feng-Ming
    Fu, Zheng
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (01): : 136 - 141
  • [26] [Fluorine-18]Fluorodeoxyglucose positron emission tomography, DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck
    Jacob, R
    Welkoborsky, HJ
    Mann, WJ
    Jauch, M
    Amedee, R
    ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES, 2001, 63 (05): : 307 - 313
  • [27] Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
    Rigo, P
    Paulus, P
    Kaschten, BJ
    Hustinx, R
    Bury, T
    Jerusalem, G
    Benoit, T
    FoidartWillems, J
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1996, 23 (12): : 1641 - 1674
  • [28] Assessment of incidental focal colorectal uptake by analysis of fluorine-18 fluorodeoxyglucose positron emission tomography parameters
    Lee, Haejun
    Hwang, Kyung-Hoon
    Kwon, Kwang An
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (17) : 5634 - 5645
  • [29] Usefulness of Fluorine-18 Fluorodeoxyglucose-Positron Emission Tomography in Management Strategy for Thymic Epithelial Tumors
    Matsumoto, Isao
    Oda, Makoto
    Takizawa, Masaya
    Waseda, Ryuichi
    Nakajima, Kenichi
    Kawano, Masaya
    Mochizuki, Takafumi
    Ikeda, Hiroko
    Watanabe, Go
    ANNALS OF THORACIC SURGERY, 2013, 95 (01) : 305 - 311
  • [30] Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?
    C. S. Brock
    S. R. Meikle
    P. Price
    European Journal of Nuclear Medicine, 1997, 24 : 691 - 705